ProCE Banner Activity

Precise Therapy for Patients With AML: Experts Discuss Clinical Challenges and Future Directions

Multimedia
Watch this on-demand Webcast from the CCO AML satellite at ASCO 2019, featuring expert discussion on key clinical biomarkers; new antibody-based therapies; treatment strategies for newly diagnosed AML and AML positive for IDH or FLT3 mutations; and emerging molecular targets.

Released: July 10, 2019

Expiration: July 08, 2020

No longer available for credit.

Share

Faculty

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Ellen K. Ritchie

Ellen K. Ritchie, MD

Associate Professor
Division of Hematology and Oncology
Department of Medicine
Weill Cornell Medical College
New York, New York

Eytan M. Stein

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Agios Pharmaceuticals

Boston Biomedical

Celgene TEXT Only

Daiichi Sankyo, Inc.

Learning Objectives

  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, and therapeutic decisions
  • Assess the available evidence to optimally integrate antibody–drug conjugates and other antibody-based therapies in AML
  • Plan evidence-based therapeutic strategies using novel formulations and refinements of conventional chemotherapy
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations
  • Manage treatment-related toxicities associated with novel therapeutics
  • Identify patients with AML who may benefit from enrollment on clinical trials evaluating next-generation cytotoxics, epigenetic treatments, immunotherapies, and targeted agents

Program Director Disclosure

Program Director

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received consulting fees from AbbVie, Agios, Amgen, Astellas, Bristol-Myers Squibb, MacroGenics, Orsenix, and Xencor.

Faculty Disclosure

Primary Author

Ellen K. Ritchie, MD

Associate Professor
Division of Hematology and Oncology
Department of Medicine
Weill Cornell Medical College
New York, New York

Ellen K. Ritchie, MD, has disclosed that she has received consulting fees from Agios, Celgene, Genentech, Novartis, and Pfizer; funding for research support from Jazz, and fees for non-CME/CE services from Incyte.

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M. Stein, MD, has disclosed that he has received consulting fees from Agios, Astellas, Celgene, Daiichi-Sankyo, Genentech, PTC Therapeutics, and Syros, and ownership interest with Auron.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has reported that his spouse has ownership interest and salary from AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina Stacy, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.